Information Provided By:
Fly News Breaks for December 26, 2019
AGN, ABBV
Dec 26, 2019 | 08:13 EDT
Cowen analyst Steve Scala raised his price target on Abbvie (ABBV) to $98 from $90 following Allergan's (AGN) FDA approval for Ubrelvy, which the analyst views as an important milestone for Abbvie. The analyst updated his model ahead of its Q4 results which includes its acquisition of Abbvie as his estimates reflect earnings are largely intact on slightly lower sales forecasts. Scala reiterated his Outperform rating on Abbvie shares.